{"nctId":"NCT01254188","briefTitle":"Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients","startDateStruct":{"date":"2011-04"},"conditions":["Chronic Myeloid Leukemia"],"count":421,"armGroups":[{"label":"Nilotinib","type":"EXPERIMENTAL","interventionNames":["Drug: Nilotinib"]}],"interventions":[{"name":"Nilotinib","otherNames":["AMN107"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Patients with chronic myeloid leukemia in the chronic phase diagnosed within 6 months of study entry\n\nExclusion Criteria:\n\n* Treatment with tyrosine kinase inhibitor or other antileukemic agents or treatments (including HSCT) for longer than 2 weeks, with exception of hydroxyurea and/or anagrelide\n* Uncontrolled congestive heart failure or hypertension\n* Myocardial infarction or unstable angina pectoris within past 12 months\n* Known T315I mutations\n* QTcF \\>450 msec\n* Significant arrhythmias\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Patients Achieving MMR by 12 Months","description":"MMR is defined as BCR-ABL ratio (%) on IS \\<= 0.1% (corresponds to \\>=3 log reduction of BCR-ABL transcripts from standardized baseline value). Clopper-Pearson method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Molecular Response at 24 Months","description":"Estimated median time to first MMR by Kaplan-Meier method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Major Molecular Response","description":"Kaplan-Meier estimates of duration of first MMR among patients who achieved MMR (FAS) Duration of first MMR (months) = (Minimum date of (loss of first MMR , CML-related death, progression to AP/BC during study treatment, censoring) - date of first MMR + 1) / 30.4375","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Cytogenetic Response","description":"Complete cytogenetic response (CCyR) is defined as a value of 0% Ph+ metaphases in bone marrow.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Estimated to Maintain Their First CCyR for 6, 12, 18, and 24 Months After the First CCyR Was Achieved as Determined by Kaplan Meier Estimatation.","description":"\\* CCyR = 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics.\n\nDuration of first CCyR (months) = (date of CCyR loss or censoring - date of first CCyR +1) / 30.4375","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"OS was defined as the time between date of study entry and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates of Progression-free Survival","description":"PFS was defined as the time from the date of study entry to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates of Failure-free Survival","description":"Time to event (months) = (date of event or censoring - date of study entry + 1) / 30.4375. Date of event is the earliest date of the following events during treatment : discontinuation of nilotinib for nilotinib-related adverse events, death due to any cause, progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR. Time is censored at the date of last assessment in the trial for patients without event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":97,"n":421},"commonTop":["THROMBOCYTOPENIA","HEADACHE","RASH","LIPASE INCREASED","NAUSEA"]}}}